# Deep Intelligent Pharma

> Deep Intelligent Pharma is a VC fund backing Therapeutics and Medical. See 2 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Singapore, Singapore
- Total investments: 2
- Last investment: Feb 2026
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/%E6%B7%B1%E5%BA%A6%E6%99%BA%E8%80%80/
- Website: https://www.dip-ai.com/

Deep Intelligent Pharma (DIP) is a Singapore-based AI company that helps pharmaceutical and biotech companies run clinical trials faster, cheaper, and with fewer mistakes. Its AI platform automates many slow and manual tasks, such as writing trial documents, designing studies, analyzing data, translating medical content for global regulators, andpreparing regulatory submissions. By using thousands of small AI agents supervised by experts, DIP not only saves time but also helps improve the chance that a clinical trial will succeed. Its technology has already been proven in real cases, including an AI-written protocol approved by Japan’s regulator with no revisions. Today, DIP works with over 1,000 life science companies worldwide, including major names like Bayer, Johnson & Johnson, and Roche.

## Contacts

5 contacts available for Deep Intelligent Pharma. Shizune tracks 2 team members at Deep Intelligent Pharma. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/deep-intelligent-pharma?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Therapeutics | 2 | 100% |
| Medical | 1 | 50% |
| Health Care | 1 | 50% |
| Biotechnology | 1 | 50% |
| Product Research | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 50% |
| Series B | 1 | 50% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Gary Song | CTO | 0 | — |
| Hygeia Li | Founder and CEO | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Imbioray | Imbioray is a biotechnology company that specializes in cellular immunotherapy for tumors and immune diseases. The company engages in the development of global CAR-NK and tiNK cell therapy drugs and is committed to solving the treatment of clinically unmet diseases. | $28.8M | Series B | Feb 05, 2026 |  |
| Kinco Biotechnology | Kinco Biotech is a gene therapy product developer that develops platforms for gene therapy research and development, including viral vector construction and optimization, large-scale cell culture and virus production processes, quality control systems, and preclinical validation. |  | Series A | Dec 01, 2025 |  |

2 of 2 investments shown.

## Co-investors
- Genesis Interactive — VC Fund, 1 deal together
- Hainan Yuque Investment — VC Fund, 1 deal together
- Hangzhou Xiner Technology — VC Fund, 1 deal together
- [Longmen Capital](https://shizune.co/investors/profile/longmen-capital) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Deep Intelligent Pharma invest in?

Deep Intelligent Pharma invests primarily in Therapeutics, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 2 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Deep Intelligent Pharma?

Public channels for Deep Intelligent Pharma include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Deep Intelligent Pharma?

The team at Deep Intelligent Pharma includes Gary Song (CTO) and Hygeia Li (Founder and CEO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co